<DOC>
	<DOCNO>NCT01792570</DOCNO>
	<brief_summary>Clinical approach HIV infection treatment base use highly active antiretroviral therapy ( HAART ) recent national international guideline guide HIV therapy recommend use triple-combination therapy use antiretrovirals 2 nucleos ( ) ide inhibitor [ N ( n ) RTI ] backbone plus third drug chosen among boosted protease inhibitor ( PI/r ) , nonnucleoside inhibitor ( NNRTI ) integrase inhibitor ( II ) . In spite evident efficacy HAART , demonstrate survival increasing , long term side effect , example impact renal function , remain principal problem . In patient risk factor renal disease , reduction eGRF ( estimate Glomerular Filtration Rate ) 90 60 mL/min/1,73 m2 could already consider risk condition [ 1,2 ] . Efficacy HAART , increase medium survival parallel decrease mortality , underlined necessity reflect long term HAART effect [ 3 ] . There many evidence HAART-related toxicity , spite necessity life-saving therapy , focus additional cost situation , term health well term economic cost . Particular attention focus impact drug renal function , tenofovir , especially tubule , without forget modification lipid bone metabolism . According study evidence potential recently introduce molecule [ 4,5 ] , investigator need realize study deepen feasibility dual-therapy permit exclude NRTIs backbone , aim prevent NRTIs-related long-term toxicity . The investigator design prospective randomize controlled trial , open-label , duration 96 week , compare efficacy dual-therapy base rilpivirine 25mg plus darunavir 800mg/ritonavir 100mg QD , HIV-positive subject suppress viremia least 3 month . In fact , data association drug , show safe , well tolerate , strong pharmacological synergy , without nucleos ( ) idic backbone , necessity minimize cost toxicity-related become increasingly compel . According clinical experience literature data , investigator hope study show positive result term immune-virological efficacy , well term decrease VACS index - complex parameter purpose quantify general organic decay - marker lipid bone metabolism , group receive dual-therapy versus group standard therapy .</brief_summary>
	<brief_title>DRV/r + RPV QD : Efficacy Toxicity Reduction</brief_title>
	<detailed_description>Pilot , phase III prospective , randomize , open-label , multicentric control study , offer novel dual-therapy regimen include RPV 25mg + DRV 800mg/rtv 100mg QD HIV+ subject suppress viremia . 132 HIV+ subject randomize , 1:1 , switch RPV+DRV/r versus continue triple-drug therapy . Subjects switch PI/r-containing regimen . The duration study 96 week patient stratify accord HCV serostatus ( Ab positive negative ) , age ( &gt; &lt; 50 year ) , immunological status ( CD4 &lt; 200/µL ; CD4=200-500/µL ; CD4 &gt; 500/µL ) . It plan enroll least 30 % female subject . Follow-up visit perform 4 , 8 , 12 , 24 , 36 , 48 , 60 , 72 , 96 week ( laboratory physical examination ) . Effectiveness measure determination HIV-RNA , safety evaluate determination AST , ALT , creatinine , plasmatic urinary phosphate , albuminuria , total cholesterol , HDL LDL cholesterol , triglycerides follow-up visit .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Rilpivirine</mesh_term>
	<criteria>Adult HIV+ subject ( &gt; 18 year old ) , give signing informed consent ; Any HAART treatment least 12 month ; Current treatment PI/rcontaining regimen initiate least 6 month earlier ; HIVRNA &lt; 50 cp/mL least 3 month , without viral blip due virologic failure time ; Any nadir CD4 lymphocytes ; Current CD4 count &gt; 100 cell/uL ; eGFRs &gt; 60 mL/min/1.73 m2 . Previous drug resistance genotypic test show presence RPV ( RT : K101E/P , E138A/G/K/Q/R , V179L , Y181C/I/V , Y188L , H221Y , F227C , M230I/L ) DRV ( protease : V11I , V32I , L33F , I47V , I50V , I54M/L , T74P , L76V , I84V , L89V ) resistance associate mutation ( RAM ) , accord November 2011 IASUSA list ; ChildPugh C grade 34 AST ALT value ; Acute cardiovascular event within 6 month ; AIDS event within 6 month ; Current IVDU ; HBsAg + ; Pregnancy lactation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>darunavir</keyword>
	<keyword>rilpivirine</keyword>
	<keyword>strategic study</keyword>
</DOC>